Efficacy and Tolerance of Tocilizumab In Takayasu Arteritis

Sponsor
Assistance Publique - Hôpitaux de Paris
Study ID
NCT02101333
Phase
PHASE3
Status
Completed

Conditions

  • TAKAYASU ARTERITIS

Eligibility Criteria

Sex
ALL
Age
18 Years - 77 Years
Healthy Volunteers
Not accepted

Interventions

  • Tocilizumab — DRUG
    intravenous injection 8 mg/kg, monthly during 6 months

Study Details

First-line tocilizumab treatment during 6 months could permit rapid steroid-tapering and induction of remission in Takayasu arteritis (TA).

Key Dates

Start date
Jun 10, 2014
Status verified
Jul 2020
Primary completion
Dec 10, 2018
Completion
Feb 1, 2019

Study Design

Enrollment
18 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: TOCILIZUMAB MONTHLY DURING 6
    intravenous injection, 8 mg/kg, monthly during 6 months

Primary Outcome Measure

number of good responders without prednisone after 6-months tocilizumab treatment [ Time Frame: 6 months ]

Related Studies